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1. ACRONYMS AND ABBREVIATIONS 
 
NCD  Non-communicable disease 
CVD  Cardiovascular disease 
DM  Diabetes Mellitus 
T1DM  Diabetes Mellitus type 1 
T2DM  Diabetes Mellitus type 2 
HG  Hyperglycaemia 
HIV  Human immunodeficiency virus 
PLHIV  People living with HIV 
ARV  Antiretroviral drug 
ART  Antiretroviral therapy 
HAART  Highly active antiretroviral therapy 
RBG  Random Blood Glucose 
FBG  Fasting Blood Glucose 
OGTT  Oral Glucose Tolerance Test 
SBT  Systolic Blood Pressure 
DBT  Diastolic Blood Pressure 
CTC  Care and Treatment Centre 
OPD  Outpatient Clinic 
HDI  Human Development Index  





“Diabetes and Hyperglycaemia: A cross-sectional study investigating proportions, risk factors 
and knowledge of disease among HIV positive and Outpatients at Kibosho Hospital, 
Tanzania” 
 
Degree Project, Programme in Medicine, 
Linda Degeryd, Department of Infectious Diseases. 
Sahlgrenska University Hospital, Gothenburg, Sweden, 2019.  
 
BACKGROUND 
Non-communicable diseases (NCDs) are increasing worldwide and are responsible for seven 
out of ten deaths each year. Some of the NCDs are asymptomatic even though they are health 
threatening. Detection, screening and treatment are key components of the global response to 
NCDs. People living with HIV (PLHIV) on antiretroviral treatment (ART) have been 
suggested to have an increased risk of developing NCDs like diabetes (DM).  
AIM 
The primary aim of this study was to investigate the proportions of DM and hyperglycaemia 
(HG) among PLHIV and patients visiting the Outpatient Department at Kibosho Hospital. 
Secondary aims were to investigate knowledge, treatment, adherence to treatment, education 
and complications secondary to DM.  
METHODS 
This was a cross-sectional study taking place at Kibosho Hospital, Tanzania for eight weeks. 
We used a structured questionnaire was used in combination with measurements of weight, 
height, waist circumference, blood pressure and blood glucose.  
RESULTS 
After exclusion, 390 participants remained for analyse. The proportions of DM (4.0%) and 
HG (1.7%) were lower among PLHIV compared to other studies in the field. Overweight, 
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hypertension and abdominal obesity were more common among patients visiting the 
Outpatient Department. Risk factors associated with DM was age (OR 1.03; 95 % CI 1.02-
1.1) and with HG hypertension (OR 3.66; 95 % CI 1.63-9.03). We also found “higher-than-
optimal” mean FBG at both facilities which was associated with hypertension (B = 2.25; 95 
% CI 0.88 – 3.62), smoking (B= -0.87; 95 % CI (-)1.58 – (-)0.17) and female gender (B= -
1.65; 95 % CI (-)3.26 – (-)0.04). PLHIV were less adherent to DM medications compared to 
ART and suffered from multiple and severe complication secondary to DM. Half of the 
participants did not know any DM risk factor.   
CONCLUSIONS 
The proportion of DM among PLHIV was lower than expected and when compared to other 
studies in the field. However, the small number of PLHIV with diagnosed DM makes it hard 
to draw conclusions whether HIV infection and ART are associated with DM, but our general 
findings support the importance of screening for NCDs in the community. 














3.1 THE GLOBAL BURDEN OF NON-COMMUNICABLE AND COMMUNICABLE 
DISEASES 
 
Non-communicable diseases (NCDs) are a worldwide threat to the public health and are 
responsible for seven out of ten deaths globally each year. Translated into numbers, this 
correlates to 41 million deaths. Even though the NCDs are more common in older people, 15 
out of 41 million deaths occur in the ages between 30 and 69 (1). The World Health 
Organization (WHO) estimates that the economic loss due to premature death caused by 
NCDs will reach seven trillion USD in 2030 (2). Another threat to the worlds young 
population and the global health are communicable diseases such as malaria and human 
immunodeficiency virus (HIV). Thanks to the HIV/AIDS Programme, there has been a 
massive reduction in new HIV infections and within seven years the incidence in the East and 
Southern Africa has decreased with 30 %. Although HIV remains Africas most significant 
public health challenges the situation is referred to as stabile. In contrast, the WHOs Annual 
Report from 2017 showed an increase of NCDs (3). Due to nutritional transition to a modern 
diet consisting of processed food, almost all countries in the Middle East and north Africa 
have faced a shift in burden of disease from communicable to non-communicable (4).  
3.2 NON-COMMUNICABLE DISEASES 
NCDs are the result of a combination of physiological, environmental, genetical, and 
behavioural factors and tend to be chronic or of long duration and medications are often 
needed to control the diseases (1). Risk factors for developing NCDs can be divided into 
modifiable behavioural, metabolic, hereditary, and socioeconomic. Examples of behavioural 
risk factors are tobacco use, physical inactivity, harmful use of alcohol, and an unhealthy diet 
including access salt, fat, and sugar. Metabolic risk factors are high blood pressure, 
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overweight and obesity, hyperglycaemia (HG=high blood sugar levels), and hyperlipidaemia 
(high blood lipids). Poverty is closely linked to NCDs and people who are living in a 
socioeconomical disadvantaged environment have an increased risk of being exposed to 
tobacco, harmful air pollution, and unhealthy diet (1, 5). The majority (85 %) of the 15 
million premature deaths in NCDs occur in low- and middle-income countries (1). 
Among the NCDs, cardiovascular diseases (CVDs) such as myocardial infarction and stroke 
causes the highest number of deaths per year (17.9 million) and diabetes mellitus comes in 
fourth place with 1.6 million deaths per year (1).  
3.3 DIABETES MELLITUS  
Diabetes mellitus (DM) is a chronic disease that is characterized by elevated levels of blood 
glucose. It occurs either when the pancreas does not produce insulin hormone (type 1/T1DM) 
or when the cells in the body are unable to use the insulin that the pancreas produces (type 
2/T2DM) (6). T2DM accounts for 90 % of all DM worldwide (7). T1DM is more often 
diagnosed in younger ages and because of its severity patients are dependent on lifelong 
insulin treatment for survival. Today, the cause of T1DM is unknown and cannot be cured (6). 
The development of T2DM is strongly connected to behavioral and metabolic risk factors and 
can be prevented with physical exercise, healthy eating, no smoking, and by controlling blood 
pressure and blood lipids (6). Age and pregnancy are also risk factors for developing T2DM.  
The aim of treatment of DM is to achieve and maintain normal blood glucose levels and 
thereby to prevent progress of the disease, acute and long-term complications, and premature 
death. Glucose levels depend on several factors such as food intake, duration of diabetes, 
conditions such as infection and inflammation, age, co-morbidities, physical activity, and 
medications (8). Normal random blood glucose for the majority of healthy individuals is 4.0-
11.1 mmol/l (8). Both T1DM and T2DM are progressive diseases and without correct 
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treatment complications will occur. The treatment of T1DM is dependent on life-long insulin 
injections and the primary treatment of T2DM are lifestyle changes in combination with 
antidiabetic pills. In some cases of severe or badly controlled T2DM, insulin is needed (6). As 
lifestyle advice, reduction of body weight and abdominal fat are essential to prevent and 
control DM (9).  
3.4 AVAILABILITY AND COST OF MEDICINE 
Availability and cost of medicines like insulin and metformin are problematic in low-and 
middle-income countries. Because of this, prevention of DM is most important to maintain a 
good public health. In WHOs Non-communicable Disease Country Capacity Survey from 
2015, 117 Member States were asked to rate the availability of essential DM medicines and 
basic technologies in public funded pharmacies. In the African WHO Region, only 40 % of 
the countries had Insulin available in 50 % or more of the public facilities or pharmacies. In 
the American and European WHO Regions the availability of insulin was more than double. 
For oral DM medications, approximately 50 % of the countries in the African WHO Regions 
reported a availability in 50 % or more of the public facilities and pharmacies (10). Another 
problem is the storage of insulin, because it needs to be kept in a fridge until use. In 2017, 65 
% of the households in Tanzania had access to electricity (11).  
3.5 THE METABOLIC SYNDROME 
Dysfunctional insulin production or increased insulin resistance is a mandatory component in 
the metabolic syndrome, which is a cluster of overweight, hypertension, and elevated blood 
lipids (10). The underlying cause is not fully clarified, but central obesity and insulin 
resistance are significant risk factors. Excess of abdominal fat has been proven to alone be 
superior to BMI in order to indicate risk of T2DM and metabolic syndrome (9). Abdominal 
fat can easily be measured by the waist circumference or waist-hip ratio and what is 
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considered to be increased circumference depends on ethnicity and gender (7, 9). Other 
factors that may have effect on the development of the metabolic syndrome are hormonal 
changes, inflammatory and proinflammatory conditions, ageing, and lack of physical activity 
(7). Nowadays, women living in Middle East and north African regions suffers the highest 
risk of metabolic diseases globally. The risk for men in this aspect was  ranked in second 
place globally (4).   
3.6 COMPLICATIONS OF DIABETES AND HYPERGLYCEMIA  
Long term complications due to elevated levels of blood glucose are retinopathy, neuropathy, 
nephropathy, decreased wound healing, amputation, and premature death directly or indirectly 
by increased risk of CVD (10). In 2012, DM caused 1.5 million deaths directly and 
additionally 2.2 million deaths by increasing the risk of  myocardial infarction and stroke (10, 
12). Even patients with higher-than-optimal glucose levels, but below levels of DM, suffer an 
increased risk of developing CVD (13). Long-term complications and premature deaths 
secondary to DM are preventable, without major costs for the individuals and society. 
Screening is an effective way to identify individuals with high risk of developing diabetes and 
accessibility to treatment with good adherence are necessary to prevent progress of disease.  
3.7 AFRICA AND UNITED REPUBLIC OF TANZANIA 
The United Republic of Tanzania is located by the coastline in Sub-Sharan Africa, East region 
and in 2018, the population was 56.3 million (14). According to The Human Development 
Index (HDI), which is a composite statistic of life expectancy, income per capita, and 
education, Tanzania is considered to be a low human development country. Poverty is 
specially common among Tanzanian women as a result of low education and non-income-
generating activities such as agriculture and household chores (15). When it comes to life 
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expectancy, Tanzania’s most significant health problem and threat to survival among young 
are the communicable diseases malaria and HIV (15).  
3.8 HIV-INFECTION 
HIV was first isolated in 1983 and was then identified as the causative agent of AIDS. The 
first antiretroviral drug (ARV) came 1987, but the real revolution in HIV treatment came in 
the middle of the 1990s, when various ARVs were used in combination (16). According to the 
latest data from 2017 there are 36.9 million people living with HIV (PLHIV) globally, among 
whom 22 million are on ART. The most affected areas are low- and middle income countries, 
particularly Sub-Saharan Africa (SSA) (17). In the United Republic of Tanzania, the 
prevalence of HIV in 2018 was 4.6 % (18).  
 
3.9 THE LINK BETWEEN HIV-INFECTION AND DIABETES MELLITUS 
PLHIV are getting older because of ART and non-development of AIDS (19). Since ageing is 
a risk factor for NCDs, DM among PLHIV are increasing as well. The total prevalence of 
both types of DM in Tanzania in 2016 was 4.3 % (20). There are studies presenting a higher 
frequency of DM among PLHIV on ART (15-18%) compared to healthy uninfected 
individuals (21-23).  
However, evidence of HIV-infection and ART as independent risk factors for T2DM are in 
conflict (19) and studies have shown mixed results (21). In studies showing a higher 
prevalence of T2DM in PLHIV, multiple risk factors associated with development of DM are 
seen more frequently in HIV-positive patients. Because of that, HIV-infection has been 




3.10 KILIMANJARO REGION AND KIBOSHO HOSPITAL 
 
The Kilimanjaro region is one of 26 regions in Tanzania, located in the northern part at the 
border to Kenya. When it comes to health care, Kilimanjaro is considered to be one of 
Tanzania’s most developed regions. Thanks to the attraction Mount Kilimanjaro and the 
fertile landscape surrounding the mountain, tourism and agriculture are two major sources of 
income to individuals living in the region. Kibosho Hospital is located in Moshi rural area and 
in 2018 the assigned catchment included 273 507 people. Hospital clinics of certain interest 
are the Care and Treatment Clinic (CTC) and the Outpatient Department (OPD). The CTC are 
responsible for patients who needs regular follow up due to diseases like HIV/AIDS and 
tuberculosis. Planed follow up, prescription of ART, worsened health status or other medical 
situation requiring medical assistance are the most common reason for encounter. PLHIV 
with good response to ART and without additional health issues are considered as stabile and 
thereby committed to smaller health centers. The regional HIV-prevalence is estimated to 3-5 
% (25). The OPD is the largest clinic at Kibosho Hospital and responsible for pre- and 
postoperative care, regular follow up and newly added medical conditions of varying 
emergency. Because of hard terrain and poor infrastructure in the hospital surroundings very 
few patients with emergent or poor health condition reaches the hospital by their own. This 








4. SPECIFIC OBJECTIVES 
  
The primary objective of this study was to determine the proportion of DM and HG and 
associated risk factors for DM among PLHIV and Outpatients attending at Kibosho Hospital. 
As second objective, to assess the knowledge of disease, education, treatment, adherence to 
treatment, and complications among participants with diagnosed DM. As a third objective, we 
wanted to investigate knowledge of risk factors for DM among all the participants.   
5. MATERIALS AND METHODS 
5.1 STUDY DESIGN  
The study was a cross-sectional study that took place at Kibosho Hospital, Tanzania between 
the 7th of October and 29th of November 2019. To bring power to the study a sample size of 
360 was demand and carried out with simplified sample size calculation with a precision level 
of 5 % and an estimated number of 5500 patients visiting the two facilities. Our aim was to 
enroll 400 patients in total to secure margin. PLHIV were recruited from CTC. Recruitment of 
Outpatients from OPD were not dependent on HIV-status and could be both HIV-positive and 
HIV-negative. Data was collected Monday to Friday between 8.00 am-13.00 pm. Inclusion 
criteria were 18 years or older and ongoing ART for PLHIV.  
We used a semi-structured questionnaire and capillary blood glucose sampling at both 
facilities. Responsible for blood glucose sampling and questionnaire at the CTC was Dr. 
Eileen Lirhunde. At the OPD, participants were recruited in the triage and all patients 
received oral information about the study. Free blood glucose test was offered as a screening 
for DM and HG. When a patient agreed to participate, he or she was brought into a quiet and 
separated consultation room where we measured the blood glucose and asked the questions. 
To minimize bias, one nurse was responsible for the questionnaire and plasma glucose 
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sampling at the OPD. Weight, height, blood pressure, and pulse rate were measured in the 
triage. Participants were interviewed while they were waiting to meet the physician in charge 
at the OPD. Patients were anonymized with ID- numbers before the interview, and data was 
recorded without connection to their personal identity. 
The questionnaire (attached in appendix) consists of both validated questions (26, 27) and 
self-designed ones to match our objectives. The original questionnaire was written in English 
by Linda Degeryd and Greta Guidotti and was then translated in written form into Swahili by 
Dr. Eileen S. Lirhunde, who also served as translator at the CTC. The questionnaire was read 
out to the patient in Swahili and answers were translated into English and recorded by Linda 
Degeryd or Greta Guidotti, who attended all the interviews. The questionnaire included 
general questions about age, gender, and lifestyle. HIV-status, time since HIV-diagnosis, time 
on ART, and adherence to ART were asked to PLHIV. All patients were asked about risk 
factors for DM and what they thought were normal levels of blood sugar. If a patient had a 
diagnosed DM, more detailed questions followed. Specific diabetes questions included 
awareness of DM-type, time since diagnose, treatment, adherence to treatment, reason for 
non-adherence, use of glucose meter in the home, diabetic education, medical history and 
knowledge of diabetes complications.  
5.2 MEASUREMENTS AND DEFINITIONS 
 
DM was defined as diagnosed type 1, type 2, or a history of gestational diabetes. 
Hyperglycemia was defined as non-diagnosed diabetes with a random blood glucose (RBG) ≥ 
11.1mmol/l or a fasting glucose (FBG) ≥ 7.0 at the time of enrolment. Fasting was defined as 
≥ 10 h since the last meal or sweetened drink. Water, tea, and coffee without sugar or milk 
were considered non-sweetened (28). The capillary glucose meter GlucoPlus was used to 
analyze capillary blood glucose levels. The machine was calibrated in the hospital laboratory. 
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During time of data collection, the two glucose meters were calibrated week number 1, 4, and 
8. Margin of error was ± 0.3 mmol/l. From the weight and height BMI was calculated and 
values ≥ 25 was defined as overweight, and ≥30 as obesity (9). Waist circumference was 
measured with patients standing in upright position. Place of measurement was midpoint, 
between the top of the iliac crest and the lower margin of the last palpable rib in the mid 
axillary line. Increased waist circumference was defined as ≥ 102 cm for men and ≥ 88 cm for 
women (9). Among patients with a systolic blood pressure ≥130 mmHg and/or a diastolic 
pressure ≥80 mmHg, a second blood pressure was measured after a rest for 10-15 minutes 
while answering the questionnaire. Mean blood pressure was calculated from the two 
measurements. Hypertension was defined as set diagnose from a health professional or SBP ≥ 
140 mmHg or DBP ≥ 90 mmHg at the time of enrolment. Physically active was defined as 
any bodily movement that requires energy expenditure for at least 30 minutes most days of 
the week (total ≥ 150 minutes/week) (29, 30). Subgroups of physical activity are physical 
work, active transport, house chores, and exercise. Exercise was defined as planned, 
structured, repetitive activities like jogging, gym, ball sports etc. Smoking was divided into 
non-smoker, current smoker previous smoker. Adherence to ART and DM medicines was 
defined as self-reported “always remember to take my medicines” in combination with 0 
missed pills the last week.  
 
5.3 STATISTICAL METHODS AND VARIABLES 
Outcomes and dependent factors were DM, HG, FBG, and RBG. Research variables and 
independent factors were age, gender, BMI, waist circumference, hypertension, smoking, and 
physically active (minutes/week). Descriptive statistics were used to investigate the 
proportions of DM and hyperglycemia, the knowledge of disease, education in DM, 
treatment, adherence, and complications secondary to DM. Paired sample T-test was used to 
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investigate the difference in mean value of FBG/RBG between PLHIV and Outpatients. 
Simple linear regression was carried out to investigate the relationship between independent 
factors and dependent factors FBG/RBG. Logistic regression was used to investigate the 
relationship between independent factors and dependent factors DM and hyperglycemia. 
Correlation was made with non-parametric Spearman analysis. Insignificant variables got a 




Ethical considerations follow the guidelines issued by the World Medical Association 
Declaration of Helsinki and the Universal Declaration of Human Rights. An ethic approval 
was made by the director of Kibosho Hospital through an ethical committee at Kilimanjaro 
Christian Medical Centre in Moshi. To minimize burden for the patients, the plasma glucose 
samples were collected by experienced staff at the hospital. All participants received oral 
information about the study and were also informed that participation was voluntary. 
Participants were free to stop the interview and withdraw their data at any time.  
Blood glucose level and blood pressure was recorded on an information sheet which was 
given to all participants (attached in appendix). The sheet also included the normal ranges of 
blood sugar and blood pressure and information regarding prevention against DM and 
hypertension through regular exercise, healthy diet, non-smoking and avoiding harmful 
alcohol consumption. When hyperglycemia was found, the physician in charge was informed 
and Kibosho Hospital was responsible to arrange follow up with oral glucose tolerance test 




7.1 CHARACTERISTICS OF THE PARTICIPANTS  
 
In total, 5492 patients visited the two facilities during our eight weeks of data collection. We 
interviewed 400 patients and 10 were later excluded because of underage, unknown HIV-
status, pregnancy and uncomplete measurements. Among the remaining 390 participants, 217 
were recruited from the OPD and 173 from the CTC (Fig. 1). All patients recruited from the 
OPD were HIV- negative.  
 
 




#patients enrolled from OPD:
n = 217








• 2 unknown HIV 
status




• 1 incomplete 
measurement




Total number of patients interviewed: 
n=400
Figure 1: Schematic presentation of the study participants.
 18 
The majority of the participants were 45-54 years old (27.9%) and 69.5% were women (Table 
1). There were 44.4% PLHIV among the participants. Christian (94.6%) was the dominating 
religion and most common tribe was Chagga (87.2%). 


































Characteristics of PLHIV (n = 173) and Outpatients (n = 217) are shown in table 2. Female 
gender dominated both groups and the mean age among Outpatients was 50 years compared 
to 47 in PLHIV. Outpatients had a higher proportion of hyperglycemia (2.8 %), DM (7.4 %), 
hypertension (35.0 %), increased waist circumference (47.0 %), overweight (32.7 %) and 
obesity (20.3 %) compared to PLHIV. There was no significant difference in proportions of 
DM and HG between groups. HIV negative individuals were older and had in average lived 
with DM for longer time (6.1 years) compared to PLHIV. SBP and DBP were higher among 
uninfected participants with a mean difference of 7 mmHg for both values between groups. 
Among uninfected 85 % were physically active compared to 75 % among PLHIV. 
The mean time with HIV infection was 7.3 years and all PLHIV received ART with a mean 
treatment time of 6.3 years. Mean CD4 cell count was 434 cells/ !!". 






DM diagnose, n (%) 7 (4.0) 16 (7.4)
Years with DM* 3.5 (3.5) 6.1 (4.6)
Hyperglycaemia, n (%)  3 (1.7) 6 (2.8)
Female gender, n (%) 110 (63.6) 161 (74.2)
Age * 47 (12.0) 50 (18.0)
Increased waist circumference, n (%) 52 (30.0) 101 (47.0)
O!"#$"%&'(, * (%) 34 (19.7) 71 (32.7)
Obese, n (%) 23 (13.3) 44 (20.3)
Hypertensive, n (%) 30 (17.0) 76 (35.0)
Mean SBP, mmHg * 121 (21.0) 128 (19.0)
Mean DBP, mmHg * 74 (13.0) 81 (11.0)
Current smoker, n (%) 14 (8.1) 4 (1.8)
Previous smoker, n (%) 29 (16.8) 13 (6.0)
Physically active, n (%) 130 (75.0) 184 (85.0)
Years with HIV infection * 7.3 (4.4) N/A
On ART, n (%) 173 (100.0) N/A




* = -./012 .31 431215617 .2 mean; SD
DM = diabetes mellitus
SBP = systolic blood pressure DBP = diastolic blood pressure
ART= antiretroviral therapy N/A = non-applicable
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7.2 PROPORTIONS OF DM AND HG  
 
Among all 390 participants the proportion of DM were 5.9%, were 5.4 % had current DM and 
0.5 % reported DM during pregnancy. The proportion of HG among undiagnosed individuals 
was 2.3%. Among participants with diagnosed DM 43% were hyperglycaemic at the time of 
enrolment. 
7.3 PROPORTIONS OF DM AND HG IN PLHIV AND OUTPATIENTS 
 
Among Outpatients the proportion of DM was 7.4% and among PLHIV 4.0%. Even the 
proportion of HG was higher among Outpatients (2.8%) compared to PLHIV (1.7%). (Fig.2) 
 
 
Figure 2. Proportions of diabetes (DM) and hyperglycaemia (HG) among people living with 




















7.4:1 RISK FACTORS ASSOCIATED WITH DM 
When the relationship between DM and present risk factors was investigated, age was 
significant in its relationship to DM (P = 0.045) with an odds ratio of 1.034 (Exp(B)) (Table 
3). Increased waist circumference was insignificant in its relationship to DM (P = 0.055). 
Insignificant variables not shown in the table are hypertension, smoking, physical inactivity, 
and gender. BMI was excluded because of correlation with waist circumference. 
Table 3. The association between variables age and increased waist circumference and 
dependent factor diabetes mellitus. 
Model  B 95% Confidence interval for 
B 
Sig. Exp(B) 
(1) Age 0.034 1.02 – 1.1 0.045* 1.034 
 Increased waist 
circumference 
0.987 1.02 – 6.13 0.055* 2.683 
*Significant level p < 0.05 
 
7.4:2 RISK FACTORS ASSOCIATED WITH HG 
 
When the relationship between HG and risk factors was investigated, hypertension was 
significant in its relationship to HG (p = 0.01) with an odds ratio of 3.657 (Exp(B)). 
Insignificant variables not shown in the table are age, HIV-status, smoking, physical 
inactivity, and gender. BMI was excluded because of correlation with waist circumference 
(Table 4). 
Table 4. The association between variable hypertension and dependent factor 
hyperglycaemia. 
Model  B 95% Confidence interval for  
B 
Sig. Exp(B) 
(1) Hypertension 1,297 1,63 – 9,03 0,01* 3,657 




7.7 KNOWLEDGE OF DISEASE AND DM EDUCATION 
 
To investigate knowledge of disease among participants with DM (n = 23), we asked “Which 
type of DM do you have?”. The majority (87%) did not know their DM type while 9% 
answered DM during pregnancy and 4% answered T2DM.  
Furthermore, we asked “Have you been educated in our DM by health professionals and if 
YES, what was it regarding?  Education had been given to 21 DM patients and the education 
consisted of information about diet/weight (95.2%), body exercise (57.1%), treatment 
(medications) (33.3%), glucose meter (23.8%), preventing complications (14.3%), and others 
(9.5%) like care of wounds and feet (Fig. 3). 
 
Figure 3. Multiple answer question regarding diabetes-education from health professional to 
participants with diabetes (n=21). Education in DM-treatment (DM=diabetes mellitus) 

























7.8 DM TREATMENT AND ADHERENCE  
 
Treatment and adherence to treatment were investigated among DM patients (n = 23). The 
majority (65.2%) was treated with only pills and 13.0% used pills in combination with diet 
and exercise. Diet and exercise were also used together with insulin (4.3%) or as single 
treatment (4.3%). Thirteen percent did not have any treatment at all and (Fig. 4). 
Among Outpatients, 68.8% reported “good adherence” to DM medications and among 
PLHIV 57.1%. Outpatients also reported a higher proportion of “no good adherence” (18.8%) 
but among PLHIV there, 28.6% did not take medications at all (Fig. 5).  
Reason for not good adherence was “I forgot”, “I only take medicines when blood sugar is 
high”, or “I only take medicines when I have symptoms”. Reasons for “not taking 




Figure 4. Treatment among participants with diabetes diagnosis (n = 23). The patients with 
no treatment had history of gestational diabetes (n = 2) and preferred natural medicines  
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Figure 5. Adherence to diabetic treatment among people living with HIV (PLHIV) and 
Outpatients. DM= diabetes mellitus.   
 
7.9 ADHERENCE TO ART 
  
Among PLHIV, 91% were adherent to ART (n = 173). Reasons for non-adherence were 
travel, ran out of medicines because of blocked roads due to bad weather conditions, could 
not afford the transport or too weak to get to the hospital. 
7.10 COMPLICATIONS SECONDARY TO DM 
 
Participants with DM were asked “Has your doctor told you that you have complications 
from your DM?” and 12 out of 23 responded YES. Among PLHIV, neuropathy was the most 
common complication (57%) followed by retinopathy (43%) and 14% had history of 
amputation due to DM. Among the uninfected individuals, 38% reported retinopathy, 31% 






















Figure 6. Self-reported complications secondary to diabetes among people living with HIV 
(PLHIV) and Outpatients.  
 
7.11 KNOWLEDGE OF RISK FACTORS FOR DM 
 
All patient responded to the open question “Do you know any risk factors for developing 
DM?” (n = 390). The most common answer was “do not know” (51.3%) followed by 
unhealthy diet (40.5%), “others” (14.6%), body inactivity (8.2%), overweight/obesity (7.7%), 
family history of DM (4.4%), high blood pressure (1.5%), tobacco use (1.3%), DM during 
pregnancy (<1 %), and waist circumference (<1%). Responses recorded as “other” was 























Table 8. Multiple answer question regarding knowledge of risk factors for diabetes mellitus 
(DM) (n = 390). 
 
* Responses in combination with others was alcohol, pancreatic disease and chronic diseases 
like HIV and cancer. 
 
7.12:1 ADDITIONAL FINDINGS- MEAN DIFFERENCE OF GLUCOSE VALUE 
(FBG/RBG) IN PLHIV AND OUTPATIENTS 
 
There was a significant difference in mean FBG between Outpatients and PLHIV (p = 0.011). 
The mean FBG among PLHIV was 5.12 mmol/l and among Outpatients 6.68 mmol/l. The 





Responses to risk factors Frequency Percent
Unhealthy diet 158 40.5
Body inactivity 32 8.2
Overweight/obesity 30 7.7
Family history of DM 17 4.4
High blood pressure 6 1.5
Tobacco use 5 1.3
DM during pregnancy 3 0.8
Waist circumference 1 0.3
Others* 57 14.6
Do not know 200 51.3
Table 2: The knowledge of risk factors for DM among all the participants 
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Table 5. Mean random blood glucose (RBG) and mean fasting blood glucose (FBG) among 
people living with HIV (PLHIV) and Outpatients (n=390). 
*Significant level p=<0,05 
 
7.12:2 VARIABLES ASSOCIATED WITH FBG 
 
There was a significant relationship between variables hypertension, gender and smoking and 
dependent factor FBG (p = 0.001, p=0.044 and p=0.016 respectively). Hypertension was 
positive associated to FBG (B = 2.07) while smoking and gender were negative associated 
(B= -0.87 and B= -1.65, respectively). Insignificant variables not shown in the table are age, 
physically active and increased waist circumference. BMI was excluded because of 
correlation with waist circumference (Table 6). 
Table 6. The association between variables hypertension, smoking and gender and dependent 
factor fasting blood glucose.  
Model  B  95% Confidence Interval for 
B 
Sig. 
(1) (Constant) 7.65 6.76 – 9.08 0.000* 
 Smoking -0.87 (-)1.58 – (-)0.17 0.016* 
 Female gender  -1.65 (-)3.26 – (-)0.04  0.044* 
 Hypertension 2.25 0.88 – 3.62    0.002* 
 





Glucose status Overall PLHIV Outpatients Mean difference P-value
RBG 6.01 5.95 6.04 0.09 0.724*
FBG 5.79 5.12 6.68 1.56 0.011*
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7.12:3 VARIABLES ASSOCIATED WITH RBG 
Hypertension, increased waist circumference, and physical activity were all significant in 
their relationship to RGB (p = 0.001, 0.001, and 0.021 respectively). Both hypertension and 
increased waist circumference were positive in their association with RBG (B = 0.90 and B = 
0.85 respectively) and physical activity had a protective and negative association with RBG 
(B = -0.708). Insignificant variables not shown in the table are age, smoking, and gender. 
BMI was excluded because of correlation with waist circumference (Table 7).   
Table 7. The association between variables hypertension, increased waist circumference, 
physical activity and dependent factor random blood glucose.  
Model  B 95% Confidence Interval for 
B 
Sig. 
(1) (Constant) 6.01 5.40 – 6.60 0.000* 
 Hypertension 0.90 0.35 – 1.44 0.001* 
 Increased waist 
circumference  
0.85 0.35 – 1.35 0.001* 
 Physically active -0.71 (-)1.30 – (-)0.11 0.021* 
  















8.1 PRIMARY FINDINGS 
 
The total proportions of DM and HG among participants in this study were 5.9% and 2.3%, 
respectively. As expected, the proportion of DM was higher compared to older population 
based studies from SSA (4-4.9%) (31, 32) since this study was hospital based and NCDs are 
increasing worldwide. In 2016, the prevalence in the Kilimanjaro region (Moshi urban and 
rural areas) was similar (5.7 %) (25). The study from 2016 conducted a randomized 
household survey and used a mobile research team to collect their data during 2014-2015. 
Because of this, one might expect a bigger difference in proportions of DM (0.2%). This 
could be explained by different criteria for the DM-group. In the study from 2016, HbA1c 
was used as a diagnostic tool and describes average blood sugar for the past two to three 
months. We used current DM or history of gestational DM as criteria and undiagnosed 
participants with newly discovered high FBG/RBG were referred to as hyperglycaemic. 
According to American Diabetes Association FBG, 2-h PG value during a 75-g OGTT and 
HbA1c are equally appropriate as diagnostic tool and can be used both for screening and 
diagnose. Although, it should be mentioned that the different tools not necessarily detect 
diabetes in the same individuals (33). For example, HbA1c is inappropriate for diagnosis of 
newly onset T1DM, gestational DM, and patients with symptoms of DM for less than two 
months. This means that our proportion of 5.9 % might be higher after follow-up of 
hyperglycaemic participants and that prevalence reported in the study from 2016 might be 
underestimated.  
Among Outpatients, the proportions of DM and HG was 7.4% and 2.8 %, respectively and 
among PLHIV 4.0 % and 1.7 %. All PLHIV with DM were diagnosed with DM after being 
diagnosed with HIV and initiation of ART. Since Outpatients were actively seeking health 
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care and do not represent a proper HIV negative control group, we cannot compare the 
results. Furthermore, CVDs are probably over-represented among the Outpatients and an 
important reason for visiting the hospital. But we can compare our low proportion of DM 
among PLHIV to other studies, since they are conducted at special HIV clinics. Higher 
prevalence of T2DM among PLHIV on ART has been reported in several studies (21-24). 
Two of them are cross-sectional studies from Tanzania and England (18% and 15%, 
respectively) (22, 23). In the Tanzanian study, ART naïve PLHIV had significantly lower 
prevalence of T2DM compared to PLHIV on ART. The difference in prevalence could not be 
explained by obvious cofounders like age, waist-hip ratio, or BMI nor by ART or duration of 
ART (23). One explanation to our low proportion might be geographic differences and lower 
rates of risk factors with possible potentiating effect of ART. The theory of metabolic changes 
due to ART has been described in previous studies and relies on excess of body fat distributed 
to the abdominal area (34). PLHIV on ART in our study tended to have lower numbers of risk 
factors like overweight and obesity compared to participants in other studies which might 
explain the difference in results. But there are also studies suggesting that highly active ART 
has no effect on glucose metabolism (FBG and insulin sensitivity) but are associated with 
development of DM risk factors (35). Because of the study method, we cannot draw 
conclusions about the chain of events since that would demand following participants over 
time, from ART naïve to long time with ART. 
We found significant relationships between age and DM (OR = 1,034) and hypertension and 
HG (OR = 3,657). Age and hypertension are well established risk factors for DM and 
significant associations have been reported in previous studies as well (24). Even though 
several lines of evidence suggest abdominal obesity as a strong risk factor there was no 
significant association to DM or HG.  
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Discussing variables without significant association relationship to DM and HG, is possible 
that our sample size lacks the power to truly investigate if  PLHIV on ART suffers from an 
increased risk of developing DM as suggested by bigger studies (21, 23, 24). There is also a 
risk of losing shades by grouping scale variables into nominal variables which could have 
given us more associated risk factors. Further analysis could be run on the material to 
investigate separate risk factors impact om DM development among PLHIV without 
transforming them into category groups.  
More than half (57%) of the DM patients in this study were hyperglycaemic at the time of 
enrolment. Treatment targets in DM varies between individuals and are dependent on age, 
time with DM and co-morbidities. Previous research has shown poor achievements of 
treatment targets (40-53%) among individuals with T2DM and are associated with long time 
of DM (36). Many patients reported non-adherence to DM medicines in the morning because 
of planned hospital visits, which could be one reason for HG among DM patients. This was 
not a recommendation from the doctors, but they recognised the phenomenon and the 
importance of informing patients to take the medicines as usual. Other reasons could be poor 
adherence or insufficient treatment or doses, which were not thoroughly investigated in this 
study. Among the undiagnosed patients, 11 (3%) were hyperglycaemic at the time of 
enrolment which supports the importance of screening.  
Almost all (21/23) patients had been educated in DM by health professionals with “diet and 
weight”, “body exercise”, and “DM treatment” being the most common education topics. 
Despite this, very few patients were aware of the different types of DM and a minority (3/23) 
knew their DM type. Poor knowledge regarding DM type is presented in other studies as well 
(25). Two of them responded history of gestational DM and had no current DM-treatment. 
Regarding the question about which treatment, they were on, 19 were treated with pills which 
indicates T2DM and one with insulin who probably had T1DM. We found low rates of DM 
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awareness among participants from both facilities, even though one might think that regular 
healthcare visits would lead to better knowledge among PLHIV. Similar low awareness rates 
have been seen in other studies from Africa and indicates that patients need to be more 
included in their health situation and receive information repeatedly (23). Among DM 
patients treated with pills, the most common drugs were metformin and glibenclamide as 
single or combination treatment which corresponds to the national treatment guidelines (29). 
A minority (4/23) used “diet and exercise” in addition to medical treatment and one used “diet 
and exercise” as only treatment with satisfying effect on blood glucose levels. When we asked 
about blood sugar testing at home, one third (8/23) had a glucose meter of their own. 
Remaining ones tested blood glucose levels at the hospital between once a month to twice a 
year. The most likely explanation to this is that the majority (20/23) had T2DM which usually 
does not need daily blood glucose testing. It could also be a question of cost, since all material 
and medicines are private funded. 
PLHIV were more adherent to ART (91%) than to DM medications (57.1%) and one third of 
the HIV-positive participants with DM did not take any DM medicines at all. One possible 
reason for the difference in adherence to ART compared to DM-medications among PLHIV is 
the cost. ART is for free while pills, insulin, and equipment for home testing are self-funded. 
Even though no one answered that they could not afford their medications, we still consider 
the cost as one reason for low adherence to DM medications. This because economic situation 
is a delicate subject to discuss and self-reported answers may underestimate the truth. This 
was also confirmed by the doctors working at Kibosho Hospital who daily struggled with 
patients who could not afford investigations or treatments. Misunderstanding and/or lack of 
information between patients and physicians might also contribute to low adherence and few 
patients were aware of that DM is a chronic disease and that correct treatment with good 
adherence is important to avoid long-term complications. 
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Awareness of complications was self-reported, and eight Outpatients and four HIV-positive 
patients had been told that their complications were secondary to DM. PLHIV in general had 
more than one complication and more severe complications (amputation). Since the risk of 
developing complications secondary to DM increases with time, one might expect that 
PLHIV had lived with DM longer. On the contrary, the mean time with DM was shorter 
among PLHIV compared to Outpatients (3.5 vs. 6.1 years). Possible reasons for multiple and 
more severe complications among PLHIV are lower adherence to DM-medicines, more 
severe DM (T1DM) and the fact that two out of seven did not use medicines to control their 
DM. A weakness in the questionnaire is that we did not ask about income generative work or 
employment which makes it impossible to make a statement about the socioeconomic status 
among PLHIV.  
Half (51%) of the participants did not know any risk factor for DM. The second most 
common answer (41%) was “unhealthy diet” such as sugar and fat and the third most 
common answer was “others” in combination with alcohol. Body inactivity and 
overweight/obesity had a respondent rate of 8.2% and 7.7%, respectively. Very few (< 1%) 
were aware that age and abdominal obesity are risk factors for DM. More than half of the 
participants did not know any risk factor, which was an unsatisfying result. This identify an 
important information gap to fill in order to prevent DM and prediabetic states. Lifestyle 
intervention has been proven effective in order to prevent DM among patients with impaired 
fasting glucose and  resulted in a 43% lower incidence of DM compared to the control group 





8.2 ADDITIONAL FINDINGS 
 
” Higher-than-optimal” mean FBG were measured at both facilities which is a risk factors for 
developing CVDs (13). Individual levels of FBG > 4.9 mmol/l has showed a continuous 
association with ischemic heart disease and stroke (38). Among Outpatients, mean FBG was 
6.68 mmol/l which is, as an individual value, referred to as prediabetes (FBG 5.6-7.0 mmol/l). 
A meta-analysis published in Lancet 2006 reported that people living in SSA had the lowest 
levels of mean fasting plasma glucose among all 52 countries included in the study. The mean 
for men and women, age-standardized by sex and region, were 5.13 and 5.15 mmol/l, 
respectively. No information about HIV infection was mentioned in the characteristics of 
participants (13). These values are in line with our findings of mean FBG among PLHIV 
(5.12 mmol/l) for both genders. However, since this was a hospital-based study we cannot 
compare the high mean FBG among Outpatients with the values from the meta-analysis 
which was population based. But importance of prevent and control DM by lowering FBG 
still remains because of the increased risk of stroke and ischemic heart disease (39). Living in 
rural areas makes it hard for patients to reach the hospital by their own and bad infrastructure 
makes the transport of patients in need of acute management problematic. Because of this, 
disability or death are common outcomes of severe stroke or ischemic heart disease.   
To investigate specific variable associated to FBG, a linear regression analysis was made. The 
analysis presented a significant association between FBG and hypertension (B = 2.25; 95 % 
CI 0.88 – 3.62), smoking (B= -0.87; 95 % CI (-)1.58 – (-)0.17) and female gender (B= -1.65; 
95 % CI (-)3.26 – (-)0.04). Prevention of hypertension in order to lower FBG and prevent 
CVDs is clinically relevant while promote smoking to prevent high FBG would only be 
harmful. Discussing the protective effect of female gender, higher levels of FBG among men 
has been reported in previous studies conducted in the Kilimanjaro region, especially those 
living in urban areas (40). However, to prevent development of DM in both genders is to be 
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recommended since women suffers an increased risk of developing DM during pregnancy and 
after regression of gestational DM (41).     
Variables associated with RBG were hypertension (B=0.90; 95 % CI 0.35-1.44), increased 
waist circumference (B=0.85; 95 % CI 0.35-1.35) and physical activity (B= -0.71; 95 % CI (-
)1.30 – (-)0.11). Even though RBG is a minor predicative variable than FBG, all these 
findings are in line with recommendations how to prevent and control DM and are clinically 
relevant in order to prevent CVD as discussed above. Increased waist circumference and 
hypertension had an elevated effect on RBG and physical activity was protective by lowering 
the RBG.  
8.3 STRENGTHS AND LIMITATIONS 
 
There are some strengths and limitations in this study. One strength is the number of 
participants included in the study which gave the analysis power to investigate our objectives. 
Second, we had the same interviewers during the entire period of data collection and to 
minimize bias between facilities Linda and Greta switched facilities day by day.  
First limitation, we were not able to use Outpatients as a control group, even though, they all 
were HIV negative. This since the proportions of DM and HG probably most likely are higher 
in this group compared to a randomized control group outside the hospital. Instead, the 
Outpatients were used to compared adherence and complications secondary to DM and 
knowledge of risk factors. The second limitation is the small number of HIV positive 
participants with DM which makes it hard to draw conclusions about causality. Third, self-
reporting might contribute to both over-and underestimation of proportions. For adherence 
and physical activity, the percentage of participants with good adherence and being physically 
active may be overestimated. Fourth, the presence of both treating physicians and a Swedish 
student during the interviews may have affected the answers in both groups. Fifth, our 
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questionnaire was a combination between validated questions from previous studies and some 
new questions written by us. Unfortunately, there are gaps about socioeconomic status and 
education level that may had been useful in our analysis. Sixth, using a translator and not be 
able to understand the language which was spoken is a source of bias. Final limitation, 
capillary blood glucose measurement is inferior to venous blood glucose measurement.  
The free glucose test is one possible bias in the recruitment process. The cost is normally 
5000 Tanzanian Shilling per sample, which is comparable to five hospital travels with the 
local bus. This offer might have affected the will to participate.  
9. CONCLUSIONS 
 
As expected, proportions of DM and HG were higher among Outpatients and they also had 
higher numbers of risk factors like overweight, abdominal obesity and hypertension. The 
proportion of DM among PLHIV was lower compared to previous study results and could be 
explained by geographic differences, less risk factors and different diagnostic tools and 
diagnosis criterial. PLHIV seemed to be less adherent to their DM medications compared to 
ART which could be explained by the cost of DM medications. Poor adherence might have 
contributed to multiple and more severe complications secondary to DM among PLHIV. Age 
had a significant relationship to DM and hypertension was associated with HG. This tells us 
that NCDs like DM and hypertension are closely linked and are affecting each other and 
worthy to identify by screening.  
 
Knowledge is necessary to encourage prevention of DMT2 and to control and reduce 
complications secondary to DM. This since half of the participants did not know any risk 
factor for DM. This study will also serve as material in the upcoming project “Know your 
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numbers”, a screening program for HIV, hypertension and DM with the mission to reach rural 
areas of Kilimanjaro region. Hopefully, this report will bring knowledge and insight to the 
health professionals involved in the project and increased health to the people living in the 
catchment area of Kibosho Hospital. 
 
10. POPULÄRVETENSKAPLIG SAMMANFATTNING 
PÅ SVENSKA  
 
Diabetes är en kronisk, metabol sjukdom kopplad till stigande ålder, hereditet, övervikt, 
bukfetma och brist på fysisk aktivitet. Förekomsten av diabetes typ 2 ökar globalt i takt med 
en växande och åldrande befolkning samt en allt mer ohälsosam livsstil. Diabetes och 
förhöjda blodglukosnivåer ökar risken för hjärt- och kärlsjukdom och för tidig död, framför 
allt i låg- och medelinkomstländer. Hjärt-och kärlsjukdom och den smittsamma sjukdomen 
HIV är idag de största hoten mot folkhälsan och överlevnaden i Sub-Sahara Afrika. Den här 
studien syftar till att undersöka hur vanligt diabetes och förhöjda blodsockernivåer var bland 
patienter som besökte Kibosho Sjukhus, Tanzania. Vi ville också undersöka kunskap, 
behandling, följsamhet till behandling och komplikationer sekundära till diabetes bland 
deltagarna med diagnostiserad diabetes. Vi var också intresserade av den allmänna kunskapen 
om riskfaktorer för diabetes. Detta undersöktes under åtta veckor i en tvärsnittsstudie genom 
att samla in data från 400 patienter. Ett frågeformulär läses upp för studiedeltagarna på 
swahili och vikt, längd, midjemått, blodtryck och blodsockervärden mättes. Bland deltagarna 
rekryterades 44 % från HIV-kliniken och förekomsten av diabetes och förhöjda 
blodsockervärden jämfördes med tidigare studier inom fältet. HIV-positiva hade en lägre 
förekomst av diabetes och förhöjda blodsockervärden jämfört med HIV-positiva från tidigare 
studier och vi tror att detta beror på lägre förekomst av riskfaktorer så som övervikt, bukfetma 
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och högt blodtryck bland våra studiedeltagare. HIV-positiva med diabetes hade i regel mer än 
en komplikation och mer komplicerade komplikationer sekundära till sin sjukdom. Vi tror att 
detta beror på bristande följsamhet till diabetesmedicinering som i sig beror av kostnaden för 
DM-medicinerna. Denna tanke grundar sig i att HIV- positiva hade mycket god följsamhet till 
sina kostnadsfria HIV-mediciner. Den generella kunskapen om riskfaktorer för diabetes var 
låg och behöver förbättras genom utbildning och repetitiv information till patienter och 
allmänheten för att förhindra utveckling av diabetes och progress av sjukdomen.   
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Questionnaire for patients treated at Kibosho Hospital 
 
 Information about the study 
 
We are two medical students from Sweden working on a research project supported by the 
University of Gothenburg. Our names are Linda Degeryd and Greta Guidotti and we are 
conducting a study about diabetes and high blood pressure. The aim of this study is to 
investigate if diabetes and high blood pressure are more common among people living with 
HIV compared to uninfected individuals. We will also investigate treatment, adherence to 
treatment, complications, risk factors and general knowledge about diabetes and hypertension.  
Both people HIV-positive and HIV-negative individuals are asked to participate. You have 
been selected to represent people in the Kibosho area and we would very much like to hear 
about your current health situation. We would also like to measure your blood pressure and 
your blood glucose. We would also like to measure your weight, height and waist 
circumference. 
It is voluntary to participate, and you have the right to withdraw at any time. 
If you have questions or concerns after we are finished, you may contact medical student via 










C1) Interview information 
  C1.1) Interview ID number (in form of 001, 002, 003...): _______________ 
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C1.2) Name of facility: ___________________________________________ 
 
C1.3) Date of interview DD/MM/YYYY: ____________________________ 
 




C2.1) Weight: ___________________ 
 C2.2) Hight: ____________________ 
 C2.3) BMI: _____________________ (do not calculate during interview) 
 C2.4) Waist circumference: _________________ 
 
 C2.5) Plasma glucose   
C2.5.1)  Random glucose (without regard to the time since the last meal): __________   
 C2.5.2) Fasting glucose: ___________   
 
C2.6) Blood pressure 
C2.6.1) Systolic: _________ 




▢ Man   
▢ Woman   
 
 45 
C3.2) If your gender is female, are you pregnant at the moment? 
▢ Yes  
▢ No 
C3.3) How old are you? In years 
  Answer: ____________________________________________ 
 




▢ Other: __________________ 
 
C3.5) What is your tribe? 
▢ Chagga   
▢ Pare   
▢ None 






C4.1) What is your HIV status? 
▢ HIV-positive 
▢ HIV-negative                                                                        
▢ Do not know. 
 
C4.2) If your status is “Do not know”, would you like to get tested for HIV? (The 





C4.3) Result HIV-test after screening: 
▢ HIV-positive 
▢ HIV-negative                                                                        
If your status is “HIV-negative” or “Do not know”, continue to question C5.1.         
 
C4.4) How long ago were you diagnosed with HIV? 
Answer: ____________________________________________ 
  
C4.5) Are you taking ART to manage your HIV? 
▢ Yes 
▢ No 
▢ Do not know    
If NO or uncertain, continue to question C5.1.                                                                           
 
 




C4.7) Do you take ART as directed? 
▢ I always remember to take my ART 
▢ I rarely forget to take my ART 
▢ I frequently forget to take my ART 
 
C4.8) If you frequently forget to take your ART as directed, how many pills did 




▢ 3 or more 
 
C4.9) If you do not take your medication as regularly, why do you not take them 
as directed? (Do not read answers) 
▢ I cannot afford the cost 
▢ Medication is not easily available 
▢ I do not like to take medications 
▢ I only take them when I feel that I need them 
▢ I do not like the side effects of the medication 
▢ I prefer alternative medicine 
▢ I forget 
▢ I do not know 
▢ Other reasons: _________________________ 
 
C4.10) What was your latest CD4+ cell count? 
Answer: ____________________________________________ 
▢ I don´t know or remember my latest CD4+ number  
 
C5) Blood pressure 
C5.1) When was your blood pressure last measured by a health professional? 
▢ Within the past 12 months 
▢ 1-5 years ago 
▢ Not within the past 5 years 
▢ Never 
▢ Do not know 
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C5.2) Have you been told by a health professional that you have high blood 
pressure or hypertension? 
▢ Yes 
▢ Yes, but only during pregnancy 
▢ No  
▢ Do not know 
 
If NO, continue to question C5.15. 
 
C5.3) How long ago were you diagnosed with high blood pressure or 
hypertension? ________ 
 
C5.4) Compared to 12 months ago, is your blood pressure: 
 ▢ Better 
▢ Same 
▢ Worse 
▢ Do not know 
▢ I didn’t get my blood pressure measurement 12 months ago  
 




▢ Do not know 
 





▢ Do not know 
 
If NO, continue to question C5.11. 
 





C5.8) If you are treated with pills to manage your high blood pressure, do you 
take your medication as directed?  
▢ I always remember to take my medicine 
▢ I rarely forget to take my medicine 
▢ I frequently forget to take my medicine 
 
C5.9) If you frequently forget to take your medicine as directed, how many pills 
for high blood pressure did you miss to take this week? 
▢ 0 
▢ 1-2 
▢ 3 or more 
If 0, continue to question C5.11. 
 
C5.10) If you do not take your medication as regularly, why do you not take them 
as directed? (Do not read answers) 
▢ I cannot afford the cost 
▢ Medication is not easily available 
▢ I do not like to take medications 
▢ I only take them when I feel that I need them 
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▢ I do not like the side effects of the medication 
▢ I prefer alternative medicine 
▢ I forget 
▢ I do not know 
▢ Other reasons: _______________________ 
 
C5.11) Has a doctor in the past year recommended you to change your way of 
life, in order to lower your blood pressure? 
Yes, I have been told to: 
▢ Eat less salt 
▢ Eat less fat 
▢ Eat more fruit and vegetables 
▢ Maintain an appropriate body weight 
▢ Exercise 
▢ Quit smoking 
▢ Restrict alcohol intake 
▢ Less emotional stress 
▢ No 
▢ Do not know 
 
C5.12) Have you been told you have any complications of high blood pressure? 
▢ Yes, I have been told I have ______________________________________. 
▢ No 
▢ Do not know 
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C5.13) Are you aware of any complications of high blood pressure? (Do not read 
answers) 
▢ Complications affecting the brain (stroke, headache) 
▢ Complications affecting the heart (heart attack, heart failure) 
▢ Complications affecting the eye (hypertensive retinopathy) 
▢ Complications affecting the kidneys (renal failure) 
▢ Other:__________________________________________ 
▢ I do not know any complications of high blood pressure 
 
C5.14) Do you have any of the following in your medical history? 
▢ Stroke 
▢ Heart disease (heart attack, heart failure) 
▢ Hypertensive retinopathy (eye problem after being diagnosed with high blood 
pressure) 
▢ Renal disease (kidney failure) 
▢ None of the above 
  
C5.15) Do you know any risk factors of developing high blood pressure? (Do not 
read answers) 
▢ Unhealthy diets (excessive salt consumption, diet high in saturated fat and trans-
fat, low intake of fruits and vegetables) 
▢ Obesity 




▢ Family history of high blood pressure 
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▢ Age over 65 
▢ Co-existing disease (e.g. diabetes, kidney disease) 
▢ Other: __________________________ 
▢ Do not know any risk factors 
 
C5.16) Do you know the definition of high blood pressure?  
▢ Yes, it is above _______ systolic and/or _______diastolic 




C6.1) Have you been told by a health professional that you have diabetes? 
▢ Yes 




If NO, continue to question C6.17. 
 
C6.2) How long ago were you diagnosed with diabetes? ______________ 
 
C6.3) Which type of diabetes do you have? 
▢ Type1   
▢ Type2     
▢ Gestational (diabetes of pregnancy)  
▢ Do not know  
 
C6.4) Do you test your blood sugar at home? 
▢ Yes, I test my blood sugar every day, _________ times a day. 
▢ Yes, I test my blood sugar every week, ________ times a week. 
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▢ Yes, I test my blood sugar when I get symptoms of low or high blood sugar. 
▢ No, I only test my blood sugar when I am visiting the hospital, ______times a year  
 
If “NO, I only test my blood sugar when I am visiting the hospital”, continue to C6.7. 
 
 C6.5) What kind of glucose meter do you use? 
Answer: ______________________________________ (e.g. capillary glucose meter) 
 
C6.6) Has your glucose meter been tested at the lab to make sure it is accurate? 
▢ Yes, date: _______________________________    
▢ No, not sure 
 
C6.7) If you do not test your blood glucose at home, what is the reason for that? 
(Do not read answer) 
▢ I have not had any directions from my doctor about testing. 
▢ I do not have a glucose meter 
▢ I cannot afford a glucose meter 
▢ I am afraid of needles  
▢ I forget  
▢ Other: ____________________________________  
 
C6.8) What kind of treatment do you use controlling your diabetes? 
▢ Diet and exercise 
▢ Pills 
▢ Insulin 
▢ None   
C6.9) If you are treated with pills or insulin, do you take your diabetic 
medication as directed? 
▢ I always remember to take my insulin/pills  
▢ I rarely forget to take my insulin/pills 
▢ I frequently forget to take my insulin/pills 
 
C6.10) If you frequently forget to take your medicine as directed, how many pills 




▢ 3 or more 
 
C6.11) If you do not take your medication as regularly, why do you not take them 
as directed? (Do not read answers) 
▢ I cannot afford the cost 
▢ Medication is not easily available 
▢ I do not like to take medications 
▢ I only take them when I feel that I need them 
▢ I do not like the side effects of the medication 
▢ I prefer alternative medicine 
▢ I forget 
▢ I do not know 
▢ Other reasons: _________________________ 
 
C6.12) Have you been educated in your diabetes by health professional? 
▢ Yes 
▢ No  
 
C6.13) If you had diabetic education, was it regarding: 
▢ Diet/weight  
▢ Exercise   
▢ Glucose meter   
▢ Pills or insulin injections  
▢ Preventing complications   
▢ Other ___________ 
 
C6.14) Have you been told you have any complications of diabetes?  
▢ Yes, I have been told I have ______________________________________. 
▢ No 
▢ Do not know 
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C6.15) Are you aware of any complications to diabetes? (Do not read answer) 
             ▢   Complications affecting the eyes (retinopathy) 
▢   Complications affecting the kidneys (renal failure) 
▢  Complications affecting the nerves and /or feet (neuropathy) 
▢   Complications affecting wound healing (decreased wound healing) 
▢  Complications affecting the heart and vascular system (heart attack, artery 
occlusion)  
▢  Amputation of toes, foot or leg 
▢  I am not aware of any complications to diabetes  
 
C6.16) Do you have any of the following in your medical history? 
▢ Stroke 
▢ Heart disease (heart attack, angina pectoris) 
▢ Eye problems (retinopathy) 
▢ Renal disease (kidney failure) 
▢ Problems with nerves or/ and feet (neuropathy) 
▢ Amputation of toes, feet or leg caused by necrosis (no trauma included)  
 
C6.17) Do you know any risk factors of developing diabetes? (Do not read answer) 
▢ Age 45 or older 
▢ Overweight or Obesity 
▢ Increased waist circumference  
▢ Unhealthy diet (excessive intake of sugar and/or saturated fats) 
▢ Family history of diabetes (parent, sister or brother with diabetes) 
▢ Diabetes during pregnancy 
▢ Have high blood pressure or takes medicine for high blood pressure 
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▢ No regular exercise 
▢ Tobacco 
▢ Other: __________________________ 
▢ Do not know any risk factors 
 
C6.18) Do you know what is considered to be a normal blood glucose? 
▢ Fasting glucose under: ___________________ 
▢ Random glucose, without regard since the last meal, under: __________ 
▢ Do not know 
 
C7) Smoking 
C7.1) Do you smoke cigarettes? 
▢ Yes 
▢ No, never have 
▢ No, but I did smoke for ______ years in the past  
If NO, continue to question C8.1  
                                                                                
C7.2) On average, how many cigarettes do/did you smoke a day? 
Number of cigarettes: ______ 
  




C8.1) Do you follow a particular diet?   
▢ No particular diet  
▢ Yes, my diet consists of: ______________________________________________  
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If NO, continue to question C9.1                                                                                 
    
C8.2) How well do you do at following this diet?  
▢ Very well      
▢ Some days better than others  




C9.1) During the past month, how often have you had a drink containing 
alcohol? 
▢ Daily 
▢ Once or twice a week 
▢ 3 to 4 times a week 
▢ 1 to 3 times a month 
▢ No 
If NO, continue to question C10.1.                                                                                 
 
C9.2) During the past month, on the day that you drank alcohol, how many 
alcoholic drinks did you usually have altogether? (one drink= 1 glass of wine, 1 
glass of beer, 1 drink of hard liquor) 
▢ 1-2 drinks/day 
▢ 3-5 drinks/day 
▢ 6 or more drinks/day 
 
C10) Exercise 
C10.1) Do you exercise? 
▢ I exercise regularly _________times a week for_________ minutes. 
▢ I exercise sometimes ________times a week for_________ minutes. 
▢ I don’t exercise because__________________________________ 
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▢ I am not able to exercise because___________________________ 
 
If “do not exercise”, continue to question C10.3                                                                                 
 
C10.2) If you exercise, what type of exercise? 
Answer: ____________________________________________ 
 
C10.3) Are you physically active to/from or at work? 



















HOW TO PREVENT DIABETES AND HIGH BLOOD PRESSURE
LIFESTYLE CHANGES:
• Eat more fruit and vegetables
• Eat less fat, salt and sugar
• Exercise daily & reduce overweight
• Stop smoking
• Drink less alcohol
KNOW YOUR NUMBERS:
Your blood pressure today was: _____________mmHg
• High blood pressure is over 140/90 mmHg
Your blood sugar today was: ________________mmol/l
• High blood sugar is over 11,1 mmol/l or over 7,1 
mmol/l if it was 10 hours since your last meal or 
sweated drink
